



Research Letter | Complementary and Alternative Medicine

Presence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements

Pieter A. Cohen, MD; Bharathi Avula, PhD; Kumar Katragunta, PhD; John C. Travis, BS; Ikhlas Khan, PhD

Introduction

Since the US Food and Drug Administration (FDA) banned ephedra from dietary supplements in 2004, supplement manufacturers have promoted a complex variety of alternative botanical compounds for sports enhancement. Extracts of *Rauwolfia vomitoria* containing α -yohimbine, the caffeine-like compound methylliberine, the partial β_2 -agonist halostachine, the plant steroid turkesterone, and norepinephrine-like octopamine are all found in plants and are promoted in dietary supplements for their stimulant or anabolic effects. ¹⁻³

The FDA does not preapprove these ingredients, or any supplement ingredient, for either efficacy or safety before their introduction, but FDA inspections have found that supplement manufacturers often fail to comply with basic manufacturing standards, such as establishing the identity, purity, or composition of the final product. Given the products' potentially complex physiologic effects and concerns regarding manufacturing quality, we determined the accuracy of dietary supplement labels declaring *R vomitoria*, methylliberine, halostachine, octopamine, and turkesterone.

Methods

Dietary supplement products were included in this case series if they were labeled as containing 1 of the following ingredients: *R vomitoria*, methylliberine, turkesterone, halostachine, or octopamine. All products were purchased online, and products were excluded if the actual label did not list 1 of the 5 ingredients. Powder from the dietary supplement products was reconstituted in methanol and analyzed for the presence and quantity of the 5 ingredients and FDA-prohibited ingredients by liquid chromatography quadrupole time-of-flight mass spectrometry. See the eAppendix in Supplement 1 for additional details.

Results

Of the 63 products purchased, 6 did not list 1 of the 5 ingredients on the label; therefore, 57 products were analyzed (13 listing *R vomitoria*; 21, methylliberine; 8, turkesterone; 7, halostachine; and 8, octopamine). Twenty-three of 57 products (40%) did not contain a detectable amount of the labeled ingredient. Of the products that contained detectable amounts of the listed ingredient, the actual quantity ranged from 0.02% to 334% of the labeled quantity (**Table**). Six of 57 products (11%) contained a quantity of the ingredient within 10% of the labeled quantity.

Seven of 57 products (12%) were found to contain at least 1 FDA-prohibited ingredient (Table). Five different FDA-prohibited compounds were found, including 4 synthetic simulants, 1,4-dimethylamylamine, deterenol, octodrine, oxilofrine, and omberacetam. Six products contained 1 of these prohibited ingredients, and 1 product contained 4 different prohibited ingredients.

- Invited Commentary
- Supplemental content

Author affiliations and article information are listed at the end of this article.

Table. Presence and Quantity of Botanical-Based Ingredients in Dietary Supplements

Product code	Claim on label	Labeled ingredient and amount per serving size	Measured ingredients per serving size, mean (SD), mg	Measured vs labeled ingredient per serving size, %	Prohibited ingredients detected	Prohibited ingredients per serving size, mean (SD), mg
Rauwolfia vomitoria products ^a						
A1	Nootropic, limitless energy	R vomitoria root-bark extract 2.5 mg	ND	0	Omberacetam (Noopept) ^{b,c}	5 (0.01)
B1	Fat burner	R vomitoria root extract	ND	NP	Octodrine ^{c,d}	319 (0.001)
C1	Thermogenic	R vomitoria extract (root bark)	ND	NP	ND	NA
D1	Preworkout	R vomitoria root extract	ND	NP	1,4-DMAA ^{e,f}	2.3 (0.01)
E1	Thermogen, precardio powerhouse, fat loss, energy, motivation	R vomitoria root-bark extract	ND	NP	ND	NA
F1	Preworkout	R vomitoria root extract 1.5 mg	ND	0	ND	NA
G1	Energy, aggression	R vomitoria extract (root-bark)	ND	NP	ND	NA
H1	Preworkout	R vomitoria root extract 1.5 mg	ND	0	ND	NA
11	Preworkout	R vomitoria root extract 1.0 mg	ND	0	ND	NA
J1	No claim	R vomitoria root extract 1.0 mg	ND	0	ND	NA
K1	Preworkout	R vomitoria extract (root-bark) 225 μg	ND	0	ND	NA
L1	Weight loss, fat incinerator	R vomitoria extract (root-bark) 225 μg	ND	0	1,4-DMAA ^{e,f}	0.5 (0.01)
M1	Preworkout	R vomitoria extract (root-bark)	ND	NP	ND	NA
Methylliberine products						
N1	Thermo activator, energy, focus	Methylliberine 25 mg	33 (0.2)	133	ND	NA
01	Energy, focus	Methylliberine	130 (0.2)	NP	ND	NA
P1	Metabolism optimization	Methylliberine 100 mg	125 (0.8)	125	ND	NA
Q1	Preworkout	Methylliberine 40 mg	52 (0.2)	129	ND	NA
R1	Preworkout	Methylliberine 100 mg	61 (0.3)	61	ND	NA
S1	Preworkout	Methylliberine 100 mg	136 (0.5)	136	ND	NA
T1	No claim	Methylliberine	16 (0.5)	NP	ND	NA
U1	Preworkout	Methylliberine 40 mg	59 (0.2)	147	ND	NA
V1	Energizing nootropic	Methylliberine 40 mg	134 (0.2)	334	ND	NA
W1	Preworkout	Methylliberine 25 mg	43 (0.02)	174	ND	NA
X1	Metabolic accelerator	Methylliberine 50 mg	69 (0.5)	138	ND	NA
Y1	Mind boosting nootropic	Methylliberine 75 mg	76 (0.3)	101	ND	NA
Z1	Fat burner	Methylliberine 100 mg	111 (0.3)	111	ND	NA
A2	Nootropic, mental concentration	Methylliberine 50 mg	68 (0.1)	136	ND	NA
B2	Metabolism booster	Methylliberine 25 mg	29 (0.6)	114	ND	NA
C2	Fast acting energy, mood, focus	Methylliberine 125 mg	133 (0.5)	106	ND	NA
D2	No claim	Methylliberine 40 mg	56 (0.2)	139	ND	NA
E2	No claim	Methylliberine	76 (0.2)	NP	ND	NA
F2	No claim	Methylliberine 150 mg	171 (0.1)	114	ND	NA
G2	No claim	Methylliberine 100 mg	115 (0.3)	115	ND	NA
H2	No claim	Methylliberine 100 mg	100 (0.1)	100	ND	NA
Turkesterone products ⁹						
12	Protein synthesis, enhance strength, increase lean mass	Ajuga turkestanica extract (10% turkesterone) 500 mg	0.01 (0.003)	0.02	ND	NA
J2	Bodybuilding	Turkesterone 500 mg	ND	0	ND	NA
K2	No claim	A turkestanica extract (turkesterone) whole plant	0.02 (0.004)	NP	ND	NA
L2	No claim	A turkestanica extract (10% turkesterone) 550 mg	ND	0	ND	NA
M2	No claim	A turkestanica extract (10% turkesterone) 500 mg	0.1 (0.0)	0.1	ND	NA
N2	Premium muscle growth	A turkestanica extract (standard minimum 10% turkesterone) 300 mg	0.03 (0.01)	0.1	ND	NA
02	Testosterone anabolic support	A turkestanica extract (10% turkesterone)	ND	NP	ND	NA
P2	Bodybuilding	Turkesterone 500 mg	ND	0	ND	NA

(continued)

Table. Presence and Quantity of Botanical-Based Ingredients in Dietary Supplements (continued)

Product code	Claim on label	Labeled ingredient and amount per serving size	Measured ingredients per serving size, mean (SD), mg	Measured vs labeled ingredient per serving size, %	Prohibited ingredients detected	Prohibited ingredients per serving size, mean (SD), mg
Halostachine productsh						
Q2	Intense, sustained thermogenic effect	Halostachine HCl	ND	NP	Deterenol ^{c,i}	0.02 (0.001)
					Oxilofrine ^{c,j}	0.2 (0.02)
					1,4-DMAA ^{e,f}	10 (0.1)
					Octodrine ^{d,f}	0.8 (0.02)
R2	Highly potent fat burner	Halostachine (Halostachys capsica) 40 mg	0.5 (0.1)	1.3	ND	NA
S2	Preworkout	Halostachine	2.0 (0.2)	NP	Deterenol ^{c,i}	0.01 (0.001)
T2	Stimulant	H capsica (aerial parts) extract 30 mg	ND	NP	ND	NA
U2	Preworkout	Halostachine 40 mg	1.0 (0.2)	3.0	Deterenol ^{c,i}	0.04 (0.001)
V2	Preworkout	Halostachine 100 mg	3.0 (0.1)	2.7	ND	NA
W2	Preworkout	H capsica (aerial parts) extract (standard to 80% halostachine) 100 mg	ND	0	ND	NA
Octopamine products ^h						
X2	Preworkout intensifier	Octopamine 30 mg	28 (0.1)	94.3	ND	NA
Y2	Preworkout	Octopamine	ND	NP	ND	NA
Z2	Nootropic brain fuel	Octopamine 30 mg	28 (0.2)	94	ND	NA
A3	Stimulant, weight loss	Octopamine	0.2 (0.1)	NP	ND	NA
В3	Fat loss	Octopamine	21 (0.1)	NP	ND	NA
C3	Weight management	Octopamine	ND	NP	ND	NA
D3	Appetite suppressor, thermogenic ignitor, fat incinerator	Octopamine	ND	NP	ND	NA
E3	Far burner	Octopamine 5 mg	6 (0.1)	110	ND	NA

Abbreviations: 1,4-DMAA, 1,4-dimethylamylamine; NA, not applicable; ND, not detected; NP, not possible (estimate not possible given lack of declared quantity of ingredient on label).

- ^a R vomitoria extract was considered not detected if analyses did not detect at least 5 common R vomitoria alkaloids (ie, rauwolsine, ajmaline, serpentinine, yohimbine, and reserpine), with a limit of detection of 10 ng/mL for each alkaloid.
- ^b The mechanism of action of omberacetam is unknown; it is marketed in Russia as Noopept. The drug has never been approved for use in the US.
- ^c Ingredient is declared on label.
- ^d Octodrine was marketed as part of a multicomponent oral medication in Germany. The drug has never been approved for oral use in the US.
- e 1,4-DMAA is an analogue of 1,3-dimethylamylamine, a sympathomimetic amine introduced in nasal inhalers in the 1940s in the US. 1,4-DMAA has never been approved as a medication for use in the US or elsewhere.

- ^f The ingredient was not declared on the label.
- $^{\rm g}$ For turkesterone products, ND means not detected, with a limit of detection of 25 ng/mL.
- $^{\rm h}$ For halostachine and octopamine products, ND means not detected, with a limit of detection of 50 ng/mL.
- Deterenol is a β-agonist that was formerly available in Europe as an ophthalmologic preparation for the treatment of glaucoma. It has never been approved for use by the US Food and Drug Administration.
- j Oxilofrine is a pharmaceutical drug developed in Europe in the 1930s with cardiac stimulatory effects similar to ephedrine. The drug has never been approved for use by the US Food and Drug Administration.

Discussion

Eighty-nine percent of dietary supplement labels did not accurately declare the ingredients found in the products, and 12% of products contained FDA-prohibited ingredients. A prior study⁴ of dietary supplements, before the FDA ephedra ban, found that 6 of 12 products (50%) contained ephedra within 10% of the labeled amount. In a more recent study⁵ of caffeine content of sports supplements, 9 of 20 products (45%) contained a quantity of caffeine within 10% of the labeled quantity. In the current study, which to our knowledge is the first to quantify these 5 supplement ingredients, only 11% of products were accurately labeled and 5 different FDA-prohibited ingredients were found, including an unapproved drug available in Russia (ie, omberacetam), 3 drugs formerly available in Europe (ie, octodrine, oxilofrine, and deterenol), and 1 drug that has never been approved in any country (ie, 1,4-dimethylamylamine).⁶

The study has limitations, including that the sample size was small, only 1 sample of each brand was analyzed, and only supplements containing 1 of 5 targeted ingredients were analyzed. It is not known whether the results are generalizable to other botanical ingredients in sports supplements or

whether quantities might also vary among batches within a given brand. Given these findings, clinicians should advise consumers that supplements listing botanical ingredients with purported stimulant or anabolic effects may not be accurately labeled and may contain FDA-prohibited drugs.

ARTICI E INFORMATION

Accepted for Publication: May 21, 2023.

Published: July 17, 2023. doi:10.1001/jamanetworkopen.2023.23879

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2023 Cohen PA et al. JAMA Network Open.

Corresponding Author: Pieter A. Cohen, MD, Department of Medicine, Cambridge Health Alliance, 300 Broadway, Somerville, MA 02143 (pcohen@challiance.org).

Author Affiliations: Department of Medicine, Cambridge Health Alliance, Somerville, Massachusetts (Cohen); Department of Medicine, Harvard Medical School, Boston, Massachusetts (Cohen); National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University (Avula, Katragunta, Khan); NSF International, Ann Harbor, Michigan (Travis).

Author Contributions: Drs Cohen and Avula had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Cohen, Travis.

Acquisition, analysis, or interpretation of data: Cohen, Avula, Katragunta, Khan.

Drafting of the manuscript: Cohen, Travis, Khan.

Critical revision of the manuscript for important intellectual content: Cohen, Avula, Katragunta, Travis.

Statistical analysis: Avula, Katragunta.

Obtained funding: Khan.

Administrative, technical, or material support: Travis.

Supervision: Cohen, Khan.

Conflict of Interest Disclosures: Dr Cohen reported receiving research support from Consumers Union and the PEW Charitable Trusts, and personal fees from UptoDate outside the submitted work; in addition, he was the subject of a civil suit brought by Hi-Tech Pharmaceuticals, a supplement company, and the jury found in his favor. No other disclosures were reported.

Data Sharing Statement: See Supplement 2.

REFERENCES

- 1. Wang N. Xie YW. Li MY. et al. Simultaneous determination of five alkaloids from Rauvolfia vomitoria in rat plasma by LC-MS/MS: application to a comparative pharmacokinetic study in normal and type 2 diabetic rats. J Sep Sci. 2021;44(7):1391-1403. doi:10.1002/jssc.202000914
- 2. Wang YH, Mondal G, Butawan M, Bloomer RJ, Yates CR. Development of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for characterizing caffeine, methylliberine, and theacrine pharmacokinetics in humans. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1155:122278. doi:10.1016/j. jchromb.2020.122278
- 3. Thevis M, Koch A, Sigmund G, Thomas A, Schänzer W. Analysis of octopamine in human doping control samples. Biomed Chromatogr. 2012;26(5):610-615. doi:10.1002/bmc.1705
- 4. Haller CA, Duan M, Benowitz NL, Jacob P III. Concentrations of ephedra alkaloids and caffeine in commercial dietary supplements. J Anal Toxicol. 2004;28(3):145-151. doi:10.1093/jat/28.3.145
- 5. Cohen PA, Attipoe S, Travis J, Stevens M, Deuster P. Caffeine content of dietary supplements consumed on military bases. JAMA Intern Med. 2013;173(7):592-594. doi:10.1001/jamainternmed.2013.3254
- 6. Cohen PA, Travis JC, Vanhee C, Ohana D, Venhuis BJ. Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine DMBA) and higenamine. Clin Toxicol (Phila). 2021;59(11):975-981. doi:10.1080/15563650.2021.1894333

SUPPLEMENT 1.

eAppendix. Supplemental Methods **eReferences**

SUPPLEMENT 2.

Data Sharing Statement